All Korean contracts are produced at domestic factories… First case of COVID-19 vaccine technology transfer
[연합뉴스 자료사진]
The Korea Centers for Disease Control and Prevention (KCDC) signed a contract to supply a vaccine for NovaVax novel coronavirus infection (Corona 19) with SK Bioscience, a domestic vaccine consignment manufacturer, at the headquarters in Osong, Chungbuk at 10 am on the 16th.
The total number of vaccines introduced by the Korean government from NovaVax is 20 million people (40 million doses), and SK Bioscience produces all of it at its domestic factory. SK Bioscience previously signed a vaccine technology introduction contract with NovaVax.
The government will receive NovaVax vaccine sequentially from the second quarter through a purchase contract with SK Bioscience.
The contract signing ceremony will be attended by Chung Eun-kyung, Director of the Disease Administration and Ahn Jae-yong, CEO of SK Bioscience, and James Young, Chairman of NovaVax, will participate in video at the US headquarters. The three parties will also discuss cooperation measures with the Korea Centers for Disease Control and Prevention regarding vaccine production and supply.
NovaVax vaccine is the first COVID-19 vaccine produced in Korea through technology transfer.
The Agency for Disease Control said, “Technology transfer will not only contribute to securing original technology for vaccine development in Korea, but will also serve as an opportunity to establish a stable vaccine supply base.”
NovaVax vaccine was developed using a synthetic antigen method used for vaccination against influenza or hepatitis B.
This is different from the previous government contracts for Pfizer-Modena (mRNA) and AstraZeneca-Jansen (viral vector) vaccines.
Synthetic antigen vaccine is a method that induces an immune response by synthesizing antigenic protein and administering it to the human body by mixing it with an adjuvant. It has a long development history and is highly safe and can be stored and distributed at 2-8°C. The shelf life is 2 to 3 years. As long as
“The NovaVax vaccine, which can be produced and supplied in Korea, will contribute to the stable supply and supply of vaccines in Korea in a situation where there is an increasing uncertainty in the supply of vaccines worldwide.” 2 million doses) vaccine was secured, and we will continue to strive for early supply and rapid vaccination.”
yunhap news